TransCode Therapeutics

TransCode Therapeutics, Inc. engages in the development and commercializing of diagnostics and therapeutics for the detection and treatment of cancer. The company was founded by Robert Michael Dudley, Zdravka Medarova, and Anna Moore in January 2016 and is headquartered in Boston, MA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

TransCode Therapeutics, Inc. engages in the development and commercializing of diagnostics and therapeutics for the detection and treatment of cancer. The company was founded by Robert Michael Dudley, Zdravka Medarova, and Anna Moore in January 2016 and is headquartered in Newton, MA.

Two patients dosed; several additional patients screened for enrollment Trial to evaluate safety and tolerability of TTX-MC138 in patients with metastatic cancer TTX-MC138 is an antisense oligonucleotide conjugated to TransCode's proprietary TTX delivery system designed to inhibit microRNA-10b, a known driver of metastasis in multiple cancers Phase 1 clinical trial follows evidence of delivery and pharmacodynamic activity in prior first-in-human Phase 0 clinical trial with radiolabeled TTX-MC138 BOSTON, Sept. 17, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced dosing of the first two patients in its Phase 1 clinical trial with its lead candidate, TTX-MC138.

TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate

BOSTON, Sept. 05, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it has been awarded a $2 million Direct to Phase II Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) to support clinical evaluation of TTX-MC138, TransCode's lead therapeutic candidate.

TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate

Boston, MA — July 24, 2024 — TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (“TransCode” or the “Company”), a clinical-stage RNA oncology company committed to

TransCode Therapeutics, Inc. Announces Closing of Public Offering

TransCode Therapeutics (NASDAQ: RNAZ ) stock is taking a beating on Tuesday after the biopharmaceutical company announced the pricing for a public offering of its shares. TransCode Therapeutics is selling 10 million shares of its common stock for 30 cents each.

Why Is TransCode Therapeutics (RNAZ) Stock Down 62% Today?

Boston, MA — July 22, 2024 — TransCode Therapeutics, Inc. (Nasdaq: RNAZ), (“TransCode” or the “Company”), a clinical-stage RNA oncology company committed t

TransCode Therapeutics, Inc. Announces Pricing of Public Offering

Boston, MA – July 22, 2024 – TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (“TransCode” or the “Company”), a clinical-stage RNA oncology company committed t

TransCode Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

BOSTON, June 10, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it has received notice from the NASDAQ Stock Market LLC (Nasdaq) that the Company has regained compliance with all applicable Nasdaq listing standards. As a result, the Company's stock will remain listed and traded on the Nasdaq Stock Market.

Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements

BOSTON, May 29, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced new preliminary data from its Phase 0 clinical trial with radiolabeled TTX-MC138 suggesting anti-tumor activity. New results from the patient dosed in this trial indicate that a microdose of radiolabeled TTX-MC138 resulted in significant inhibition of the drug candidate's molecular target, miRNA-10b, in the patient's blood.

TransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138

TransCode Therapeutics (NASDAQ: RNAZ ) stock is sliding lower on Monday following its announcement of an upcoming annual shareholder meeting. TransCode Therapeutics has informed investors in RNAZ stock that the company will hold its annual shareholder meeting on June 13, 2024 at 9:30 a.m Eastern Time.

Why Is TransCode Therapeutics (RNAZ) Stock Down 14% Today?

BOSTON, May 13, 2024 (GLOBE NEWSWIRE) -- The Board and Management of TransCode Therapeutics (NASDAQ: RNAZ) today issued the following open letter to shareholders of the Company: Dear Shareholder, As you may have seen, we have filed an amended proxy statement in connection with our Annual Meeting scheduled for June 13. One of the proposals in the proxy provides for authorizing the Board of Directors, if they believe it is the best interests of the company and shareholders, to effect a reverse split of our stock.

TransCode Therapeutics Open Letter to Shareholders

BOSTON, April 15, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, announced today that the U.S. Food and Drug Administration (FDA) has completed its review of the company's Investigational New Drug (IND) application and concluded that the company may proceed with its Phase 1/2 multicenter, open-label, dose-escalation and dose-expansion study of its lead therapeutic candidate, TTX-MC138, in patients with advanced solid tumors. “We are thrilled to have obtained FDA authorization to advance TTX-MC138 into the clinic.

TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors

BOSTON, April 03, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported financial results for 2023 and recent business progress. “We believe 2023 was extremely productive and pivotal for TransCode.

TransCode Therapeutics Reports 2023 Results; Provides Business Update

BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, announced today that Daniel Vlock, M.D., has been appointed as the company's Chief Medical Officer.

TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer

BOSTON, March 11, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, reported positive proof-of-concept laboratory studies in human cells, advancing its strategic partnership with Akribion Genomics. Akribion Genomics, a German-based biotechnology start-up, is focused on a CRISPR-derived molecular complex for cancer treatment.

TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment

BOSTON, March 06, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that its Chief Scientific Officer, Zdravka Medarova, Ph.D., will present at this year's RNA Leaders Europe Congress scheduled to take place March 12-14 in Basel, Switzerland.

TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress

BOSTON, Feb. 20, 2024 (GLOBE NEWSWIRE) --  TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, reported publication of United States Patent Application titled, “Nanoparticles and Template Directed RIG-I Agonist Precursor Compositions and Uses Thereof For Cancer Therapy“ (Pub. No.: US 2024/0042070 A1; Pub.

TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode's RIG-I Agonist Immunotherapeutic

BOSTON, Jan. 31, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it has received notice from the NASDAQ Stock Market LLC (Nasdaq) that the Nasdaq has determined that the Company has regained compliance with the minimum stockholders' equity requirement under Nasdaq Listing Rule 5550(b)(1) (the Equity Rule) for continued listing on the Nasdaq Capital Market. Pursuant to Nasdaq Listing Rule 5815(d)(4)(B), the Company will be subject to a mandatory panel monitor through January 26, 2025.

Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders' Equity Requirement and Continued Listing on The Nasdaq Stock Market

BOSTON, Jan. 29, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced a co-research agreement with Debiopharm, a privately-owned Swiss-based, global biopharmaceutical company aiming to establish tomorrow's standard-of-care to cure cancer and infectious diseases. The collaboration will explore combining TransCode's proprietary TTX delivery platform with Debiopharm's expertise in targeted drug delivery to co-develop targeted nucleic acid therapeutics for cancer.

TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer

BOSTON, Jan. 22, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced the closing of its previously announced public offering of an aggregate of 5,942,623 shares of its common stock (or common stock equivalents) and warrants to purchase up to 11,885,246 shares of common stock at a combined public offering price of $1.22 per share (or per common stock equivalent) and accompanying warrants. The warrants have an exercise price of $1.22 per share, are exercisable immediately upon issuance and will expire three and one-half years from the date of issuance.

TransCode Therapeutics Announces Closing of $7.25 Million Public Offering

TransCode Therapeutics (RNAZ) will issue secondary shares and warrants, diluting its current shareholder base. The company plans to raise $7.5 million in gross proceeds from this issue.

TransCode (RNAZ) Down 50% on Issue of New Common Stock

BOSTON, Jan. 18, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced the pricing of a public offering of an aggregate of 5,942,623 shares of its common stock (or common stock equivalents) and warrants to purchase up to 11,885,246 shares of common stock at a combined public offering price of $1.22 per share (or per common stock equivalent) and accompanying warrants. The warrants will have an exercise price of $1.22 per share, will be exercisable immediately upon issuance and will expire three and one-half years from the date of issuance.

TransCode Therapeutics Announces Pricing of $7.25 Million Public Offering

BOSTON, Jan. 12, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported further steps in its previously-announced restructuring. The restructuring is intended to further reduce expenditures and enable greater concentration of company resources on a planned Phase 1 clinical trial for its lead therapeutic candidate, TTX-MC138.

TransCode Therapeutics Reports Further Restructuring to Reduce Expenses and Increased Focus on Planned Phase 1 Clinical Trial, Retirement of CEO

BOSTON, Jan. 11, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) (“TransCode” or the “Company”), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today announced that its Board of Directors has approved a 1-for-40 reverse stock split, to be effective at 12:01 a.m. Eastern Standard Time Tuesday, January 16, 2024.

TransCode Therapeutics Announces 1-for-40 Reverse Stock Split

BOSTON, Jan. 04, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (“TransCode” or the “Company”) (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced publication of an open letter to shareholders outlining the Company's progress in 2023 and objectives in 2024. The text of the letter is below.

TransCode Therapeutics Publishes Open Letter Outlining Company's Progress and Objectives

TTX-MC138 is Effective in Animal Models of Human Metastatic Pancreatic Cancer TTX-MC138 is Effective in Animal Models of Human Metastatic Pancreatic Cancer

News for TransCode Therapeutics Stock (RNAZ)